News & Trends - MedTech & Diagnostics
Ellume and Novartis secure top 10 ranking in AFR Boss Most Innovative Companies List

MedTech News: Ellume and Novartis have been recognised in the 2021 AFR BOSS top 10 innovations in the health industries category.
The Ellume COVID-19 home test is the AFR Boss winner of the Best Innovation in the health sector. The home test is an over-the-counter, rapid self-test that detects SARS-CoV-2 antigen, providing results in 15 minutes. The test includes built-in connectivity that enables real-time reporting of results to public health authorities, designed to allow better tracking of the virus while reducing the burden on the healthcare system.
Ellume CEO and founder Dr Sean Parsons, said “The AFR BOSS 10 awards are a wonderful recognition of the hard work and dedication that the entire Ellume team has invested in this ground-breaking technology over the past decade.
“I want to thank AFR BOSS 10 and their sponsors for recognising the Ellume team’s significant contribution to combating the Covid-19 pandemic. This technology isn’t created overnight and a whole lot of people have worked hard to make it happen and the AFR BOSS 10 award is terrific recognition of their efforts.”
Novartis’ MSGo is a software-as-a-service solution designed for multiple sclerosis treatment initiation for Australian patients. It combines a clinician app, a patient app and a website portal to connect healthcare professionals, nurse care teams, patients and carers. For clinicians, MSGo provides a simple treatment initiation and monitoring solution while patients stay connected to their healthcare team and have less of a paperwork burden so they can focus on managing their condition.
Richard Tew, General Manager and Country President Novartis Pharmaceuticals Australia and New Zealand, said “We are really excited to be recognised at number six of Australia’s Most Innovative Companies – Health list. It’s great to be featured alongside some really nimble and innovative healthcare companies, a true testament to the progress we are making on our business transformation journey.
“The awards review process was robust, looking at the MSGo project, as well as our internal approach to innovation, and a survey that our people filled out anonymously. I’m very proud of the result.”
Novartis appointed RxMx, founded by Australian doctors, as the technology partner for the project, due to the RxMx team’s experience and knowledge of multiple sclerosis, as well as their patient support app credentials and focus on simplifying workflow for healthcare professionals.
News & Trends - Pharmaceuticals

Clinicians call for closer monitoring of patients post CAR T therapy
Australian clinicians are raising questions about whether cancer patients need closer monitoring after receiving CAR T-cell therapy. A Peter MacCallum […]
MoreNews & Trends - MedTech & Diagnostics

Next-gen surgical mesh to fill critical gap after regulatory ban
Next-generation urogynaecological surgical mesh implants are on the horizon for women suffering from pelvic organ prolapse (POP). This development aims […]
MoreNews & Trends - Pharmaceuticals

Contraceptive lawsuit against Bayer fails
The Victorian Supreme Court has dismissed a class action against Bayer for an allegedly defective contraceptive device. Justice Andrew Keogh […]
MoreNews & Trends - Pharmaceuticals

NSW Government ignored warnings since 2018: Mental health system unravels as psychiatrists quit en masse
The New South Wales Labor government’s plan to “redesign” the state’s mental health system, while excluding psychiatrists, has sparked intense […]
More